FDA Submission Update for ONTRUZANT (BLA761100) by Samsung Bioepis
The FDA has received a supplemental application (BLA761100) for ONTRUZANT, an HER2-targeting biosimilar.
Asset / Drug
Drug and asset intelligence for ONTRUZANT with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Topline Data
July 4, 2026 · N/A
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.